Who Owns ClearLab?

ClearLab's Clear 1-Day product literature references the use of green materials, noting that 80 percent of the packaging plastic is described as environmentally conscious. This claim appears in the product description on the ClearLab website but has not been independently verified by third-party environmental certification bodies as of August 2026.

Menicon, ClearLab's parent, publishes sustainability information through its corporate website. The company's manufacturing operations in Singapore and Japan are subject to respective national environmental regulations. Menicon has not announced a formal net-zero emissions target or science-based emissions reduction commitment as of August 2026.

Contact lens waste is an industry-wide environmental concern. ClearLab's daily disposable products generate single-use waste like all daily contact lenses. The brand has not announced a dedicated recycling program comparable to Bausch and Lomb's ONE by ONE program or CooperVision's plastic neutrality initiative. Menicon's corporate sustainability efforts focus on manufacturing efficiency and product design rather than post-consumer recycling programs.

ClearLab's Beyond 1-Day is marketed as the world's first biocompatible silicone hydrogel daily disposable lens. This claim appears on the ClearLab website and in product literature. The product represents a materials innovation combining biocompatible formulation with silicone hydrogel oxygen permeability, though independent clinical awards or third-party recognition for this specific claim have not been widely documented as of August 2026.

ClearLab products are registered with the FDA as Class II medical devices, having received premarket notification (510(k)) clearance. The Miru 1day Menicon Flat Pack, manufactured at the Singapore facility, received FDA clearance under submission K102895. This regulatory clearance is a verifiable fact documented in FDA establishment registration records.

The ClearLab brand has not appeared in major consumer contact lens rankings such as the Forbes Vetted 2026 best contact lenses guide or the ContactLens.com 2026 rankings, which focus on the major global brands. ClearLab's market presence is concentrated in professional channels and Asia-Pacific distribution rather than direct consumer recognition.

No major FDA recalls specific to ClearLab branded products have been documented in FDA recall databases as of August 2026. Menicon Singapore, the manufacturing entity, is registered with the FDA as an active manufacturing establishment and is subject to FDA inspection and quality system regulations.

As a manufacturer of Class II medical devices, ClearLab products are subject to post-market surveillance requirements. Any manufacturing deviations would be managed through standard FDA recall procedures. The Singapore facility's FDA registration status is active as of 2026.

No significant controversies or regulatory enforcement actions specific to ClearLab or Menicon Singapore have been publicly documented. The brand operates at a smaller scale than the major global manufacturers, which reduces its public scrutiny profile but also limits the visibility of any quality or compliance matters.

The complex ownership history of the ClearLab brand, involving the 2007 intellectual property acquisition from 1-800 Contacts and the separate sale of manufacturing operations to Mi Gwang, is a matter of public record but has not generated controversy. Menicon has operated the brand and Singapore manufacturing independently since that time.